|HCPCS||Generic Name||Brand Name||Strength||SEER*Rx Category||Major Drug Class||Minor Drug Class||Oral (Y/N) (Descending)||FDA Approval Year||FDA Discontinuation Year||CMS Effective Date||CMS Discontinuation Date||Status|
|J9023||Avelumab||Bavencio||10mg||Immunotherapy||Checkpoint Inhibitor||PD-L1||No||2017||Jan. 1, 2018||In Use|
|J9173||Durvalumab||Imfinzi||10mg||Immunotherapy||Checkpoint Inhibitor||PD-L1||No||2017||Jan. 1, 2019||In Use|
|C9070||Tafasitamab-cxix||Monjuvi||2mg||Immunotherapy||Monoclonal Antibody||CD19||2020||Jan. 1, 2021||April 1, 2021||No Longer Used|
Found 628 results in 3 milliseconds — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.